Shree Ram Proteins Beheer

Beheer criteriumcontroles 2/4

De CEO Shree Ram Proteins is Lalitkumar Vasoya, benoemd in Nov2017, heeft een ambtstermijn van 16.25 jaar. bezit rechtstreeks 15.18% van de aandelen van het bedrijf, ter waarde ₹ 45.84M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7 jaar en 4.4 jaar.

Belangrijke informatie

Lalitkumar Vasoya

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7yrs
Eigendom CEO	15.2%
Management gemiddelde ambtstermijn	7yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Feb 28

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Mar 29

Calculating The Fair Value Of Shree Ram Proteins Limited (NSE:SRPL)

Dec 11

Shree Ram Proteins (NSE:SRPL) Seems To Use Debt Quite Sensibly

Nov 06

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Jun 19

Here's Why Shree Ram Proteins (NSE:SRPL) Has A Meaningful Debt Burden

Feb 24

Analyse CEO-vergoeding

Hoe is Lalitkumar Vasoya's beloning veranderd ten opzichte van Shree Ram Proteins's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-₹103m
Mar 31 2024	n/a	n/a	-₹96m
Dec 31 2023	n/a	n/a	-₹53m
Sep 30 2023	n/a	n/a	-₹2m
Jun 30 2023	n/a	n/a	₹27m
Mar 31 2023	₹2m	n/a	₹38m
Dec 31 2022	n/a	n/a	₹52m
Sep 30 2022	n/a	n/a	₹59m
Jun 30 2022	n/a	n/a	₹65m
Mar 31 2022	₹1m	n/a	₹61m
Dec 31 2021	n/a	n/a	₹79m
Sep 30 2021	n/a	n/a	₹64m
Jun 30 2021	n/a	n/a	₹33m
Mar 31 2021	₹1m	n/a	₹8m
Dec 31 2020	n/a	n/a	-₹11m
Sep 30 2020	n/a	n/a	-₹13m
Jun 30 2020	n/a	n/a	₹7m
Mar 31 2020	₹720k	₹720k	₹26m
Dec 31 2019	n/a	n/a	₹19m
Sep 30 2019	n/a	n/a	₹38m
Jun 30 2019	n/a	n/a	₹36m
Mar 31 2019	n/a	n/a	₹33m
Dec 31 2018	n/a	n/a	₹26m
Sep 30 2018	n/a	n/a	₹19m
Jun 30 2018	n/a	n/a	₹19m
Mar 31 2018	₹500k	₹500k	₹18m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Lalitkumar redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de Indian markt.

Compensatie versus inkomsten: De vergoeding van Lalitkumar is gestegen terwijl het bedrijf verliesgevend is.

CEO

Lalitkumar Vasoya (43 yo)

7yrs

Tenure

₹1,500,000

Compensatie

Mr. Lalitkumar Chandulal Vasoya is the Chairman and has been the Managing Director of Shree Ram Proteins Limited (formerly known as Shree Ram Protiens Limited) since November 10, 2017 and has been its Dire...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Lalitkumar Vasoya	Chairman & MD	7yrs	₹1.50m	15.18% ₹ 45.8m
Bhupendrabhai Bhadani	Company Secretary & Compliance Officer	7.8yrs	₹242.00k	geen gegevens
Krutil Parakhia	Chief Financial Officer	1.4yrs	geen gegevens	geen gegevens

7.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van SRPL is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lalitkumar Vasoya	Chairman & MD	16.3yrs	₹1.50m	15.18% ₹ 45.8m
Piyush Vasoya	Non Executive Director	7.3yrs	geen gegevens	0.19% ₹ 558.8k
Navin Singh	Non-Executive Director	1.5yrs	geen gegevens	geen gegevens
Dipti Sharma	Independent Non-Executive Director	1.4yrs	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

36yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SRPL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Shree Ram Proteins Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Shree Ram Proteins Limited Announces the Resignation of Jaykumar Deepakbhai Khatnani as Independent Director

Shree Ram Proteins Limited, Annual General Meeting, Aug 14, 2023

Less than half of directors are independent

Chairman & MD recently sold ₹15m worth of stock

Chairman & MD recently sold ₹22m worth of stock

Recent updates

First quarter 2025 earnings released: ₹0.02 loss per share (vs ₹0.01 profit in 1Q 2024)

Full year 2024 earnings released: ₹0.45 loss per share (vs ₹0.18 profit in FY 2023)

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Now 22% overvalued after recent price rise

Now 24% overvalued after recent price rise

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Less than half of directors are independent

Shree Ram Proteins Limited Announces the Resignation of Jaykumar Deepakbhai Khatnani as Independent Director

New minor risk - Share price stability

Second quarter 2024 earnings released: ₹0.09 loss per share (vs ₹0.048 profit in 2Q 2023)

Shree Ram Proteins Limited to Report Q2, 2024 Results on Nov 08, 2023

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 16%

Shree Ram Proteins Limited, Annual General Meeting, Aug 14, 2023

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Less than half of directors are independent

Full year 2023 earnings released: EPS: ₹0.18 (vs ₹0.29 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: EPS: ₹1.79 (vs ₹2.87 in FY 2022)

Investor sentiment improves as stock rises 16%

Chairman & MD recently sold ₹15m worth of stock

Chairman & MD recently sold ₹22m worth of stock

Shree Ram Proteins (NSE:SRPL) Has A Pretty Healthy Balance Sheet

Investor sentiment deteriorates as stock falls 17%

Chairman & MD recently sold ₹4.9m worth of stock

Third quarter 2023 earnings released: EPS: ₹0.25 (vs ₹0.56 in 3Q 2022)

Chairman & MD recently sold ₹2.0m worth of stock

Investor sentiment deteriorated over the past week

Non Executive Director recently sold ₹7.3m worth of stock

Non Executive Director recently bought ₹40m worth of stock

Insider recently sold ₹2.4m worth of stock

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Investor sentiment improved over the past week

Insider recently sold ₹1.7m worth of stock

Chairman & MD recently bought ₹2.4m worth of stock

Second quarter 2023 earnings released: EPS: ₹0.48 (vs ₹0.77 in 2Q 2022)

Less than half of directors are independent

Chairman & MD recently bought ₹1.6m worth of stock

Investor sentiment deteriorated over the past week

Promoter & Whole-Time Director recently sold ₹10m worth of stock

Promoter & Whole-Time Director recently sold ₹3.2m worth of stock

Promoter & Whole-Time Director recently sold ₹2.8m worth of stock

Investor sentiment deteriorated over the past week

Shree Ram Proteins Limited, Annual General Meeting, Jul 18, 2022

Does Shree Ram Proteins (NSE:SRPL) Have A Healthy Balance Sheet?

Promoter & Whole-Time Director recently sold ₹11m worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Chairman & MD recently sold ₹4.5m worth of stock

Investor sentiment deteriorated over the past week

Chairman & MD recently sold ₹2.8m worth of stock

Full year 2022 earnings released: EPS: ₹2.87 (vs ₹0.39 in FY 2021)

Chairman & MD recently sold ₹3.7m worth of stock

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Shree Ram Proteins Limited (NSE:SRPL)

Investor sentiment improved over the past week

Shree Ram Proteins (NSE:SRPL) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS ₹0.77 (vs ₹1.27 loss in 2Q 2021)

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Full year 2021 earnings released: EPS ₹0.39 (vs ₹1.22 in FY 2020)

Here's Why Shree Ram Proteins (NSE:SRPL) Has A Meaningful Debt Burden

Third quarter 2021 earnings released: ₹0.16 loss per share (vs ₹0.22 loss in 3Q 2020)

New 90-day high: ₹37.35

Shree Ram Proteins Limited Announces Board Changes